Opera Trading Capital’s MacroGenics MGNX Stock Holding History

Opera Trading Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,996	Closed	-$86K	–	135
2018 Q3	$86K	Buy	+3,996	New	+$85.2K	0.02%	136

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CPV Partners Stamford, Connecticut $224M AUM 77.2% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Opera Trading Capital's MGNX Position: Q4 2018 in Review

Opera Trading Capital sold out of MacroGenics (MGNX) in Q4 2018, closing a stake of 3,996 shares — an estimated $86K sold.

Opera Trading Capital first reported a position in MGNX in Q3 2018 and held it in 1 quarter. The position peaked at $86K in Q3 2018. 133 funds tracked by Wall St. Rank hold MGNX as of Q4 2018.

Opera Trading Capital reported no remaining MacroGenics position as of Q4 2018 after selling out during the quarter.
Opera Trading Capital sold 3,996 MacroGenics shares in Q4 2018, an estimated $86K.
Opera Trading Capital first reported a position in MacroGenics in Q3 2018 and held it in 1 quarter.
Opera Trading Capital's MacroGenics position peaked at $86K in Q3 2018.
133 funds tracked by Wall St. Rank held MacroGenics as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.